ArticleFrontiers in medicine2026
Serum Klotho as a potential biomarker for prognosis in acute ischemic stroke.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between serum Klotho levels and 90-day functional outcome in patients with acute ischemic stroke (AIS), and to assess its potential as a short-term prognostic biomarker. Methods: This single-center retrospective observational cohort study included 200 patients with AIS. Patients were divided into favorable outcome group [90-day modified Rankin Scale (mRS) 0-2, Results: Serum Klotho levels were significantly lower in patients with unfavorable outcomes than in those with favorable outcomes [579.65 (444.50, 664.12) pg/mL vs. 754.05 (656.00, 817.95) pg/mL, Conclusion: Lower early serum Klotho levels were independently associated with unfavorable 90-day outcome in patients with AIS. However, its incremental predictive value beyond established clinical variables was not statistically confirmed. Further prospective studies are needed to validate its prognostic utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.